Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.43+1.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RLMD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Operating Expenses & Income | ||||||||||||||
| R&D Expenses | 28.6 | 26.9 | 46.2 | 54.8 | 113.3 | 90.6 | 36.0 | 7.0 | 2.9 | 1.3 | 6.2 | 7.9 | 5.2 | — |
| Operating Income | (65.1) | (59.1) | (83.9) | (103.7) | (161.2) | (125.7) | (60.8) | (12.7) | (6.9) | (7.2) | (16.2) | (17.1) | (6.8) | (0.0) |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.2 | — |
| Interest & Investment Income | 3.9 | 1.4 | 3.5 | 5.2 | — | — | — | — | — | — | — | 0.0 | 0.0 | — |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | (0.0) | 0.2 | — |
| Other Non-Operating Income / Expenses | 3.2 | 1.7 | 3.9 | 4.9 | 4.2 | (0.0) | 1.4 | (4.6) | (2.0) | — | — | — | — | — |
| Earnings from Continuing Operations | — | — | — | — | — | (125.8) | (59.5) | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||
| Net Income | (4.5) | (57.4) | (80.0) | 0.0 | (157.0) | (125.8) | (59.5) | (17.3) | (9.0) | (6.3) | (3.0) | (20.8) | (19.9) | (0.0) |
| Per Share | ||||||||||||||
| Basic EPS | (0.04) | (1.45) | (2.65) | (3.28) | (5.30) | (7.16) | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.04) | (1.45) | (2.65) | (3.28) | (5.30) | (7.16) | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 112.4 | 39.5 | 30.2 | 30.1 | 29.6 | 17.6 | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 112.4 | 39.5 | 30.2 | 30.1 | 29.6 | 17.6 | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||
| EBIT | (65.1) | (59.1) | (83.9) | (103.7) | (161.2) | (125.7) | (60.8) | (12.7) | (6.9) | (7.2) | (16.2) | (17.1) | (6.8) | (0.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.